Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.60
Bid: 0.55
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.10 (18.182%)
Open: 0.60
High: 0.00
Low: 0.00
Prev. Close: 0.60
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European Health Claim Adoption for Fruitflow

28 May 2009 07:00

RNS Number : 9135S
Provexis PLC
28 May 2009
 



28 May 2009 

PROVEXIS PLC

("Provexis" or the "Company")

European Health Claim Adoption for Fruitflow

Provexis plc, the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, is pleased to announce the adoption of scientific substantiation of a health claim for the Company's Fruitflow® anti-thrombotic technology by the European Food Safety Authority ("EFSA").

The European Commission has introduced regulation aimed at harmonizing and approving nutrition and health claims on foodsEFSA intends to establish an EU-wide list of permitted claims by 2010 and health claims which do not comply will be prohibitedProvexis submitted a health claim dossier in late 2008 under Article 13(5) which regulates newly developed science or claims with proprietary data. 

Following review by the EFSA panel, it was judged that a cause and effect relationship has been established between consumption of Fruitflow® and the reduction of platelet aggregation in humans. EFSA has now adopted the scientific opinion substantiating the health claim and this will go through the final authorization procedure in the coming weeks. 

Stephen Moon, Chief Executive of Provexis plc said: 

"We understand that Fruitflow® is the first technology to have health claim adopted by EFSA under Article 13(5) of the new legislation. While the process has required intensive resource allocation over the last few months, we are supportive of the new framework, given it clears the way for scientifically-substantiated products to prevail in the market. This is a major milestone for Provexis and one which we believe will have a very positive effect on current and future commercial negotiations. It is also recognition of the quality of our business, its technologies and our scientific and regulatory capabilities.

ENQUIRIES

Provexis plc Tel.01753 752 290

Stephen Moon, CEO

Steven Morrison, COO

Arbuthnot Tel.020 7012 2000

Tom Griffiths

Alasdair Younie

END

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRGDUBBDGGCR
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.